LGL leukemia is associated with specific immunophenotypic and molecular features, particularly STAT3 and STAT5 mutations and activation of the JAK-STAT3, Fas/Fas-L and NF-κB signaling pathways. The gene discussed is STAT5B; the disease is T-cell large granular lymphocyte leukemia.